Clinical trials: Long COVID, open to volunteers
Long Covid
Antiviral Clinical Trial for Long Covid-19
The trial will test if two repurposed HIV antivirals can reduce symptom burden in adult participants with Long Covid compared to placebo. Viral infection and viral reactivation have been documented in Long Covid.
- Trial name
- NCT06511063
- Testing
- tenofovir disoproxil/emtricitabine, Selzentry
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Long COVID
Evaluation of the Effectiveness of Breathing Control Technique on Long COVID Symptoms at the Reunion University Hospital
Despite the controversy, on October 6, 2021, the World Health Organization (WHO) recognized Long Coronavirus disease (COVID) by officially defining it: " symptoms appeared 3 months after the onset of the primary infection by the…
- Trial name
- COCO-Long'Run (NCT05851859)
- Testing
- Cardiac coherence
- Where
- 2 sites in France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Long COVID
A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID
The IMPACT Long Covid Treatment clinical study (IMPACT-LC) is testing two repurposed and previously approved drugs, Maraviroc and Atorvastatin, for the treatment of non-hospitalized subjects with Long COVID.
- Trial name
- IMPACT-LC (NCT06974084)
- Testing
- Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg
- Where
- United States
- Volunteers
- 252 people
- Sponsor
- HealthBio, Inc.
Long-COVID
Long-term COVID and Rehabilitation
The proposed focuses on improving both morbidity and mortality in older Veterans and those recovering from COVID-19 by developing rehabilitation therapies to augment vascular endothelial function by combating the oxidative stress…
- Trial name
- NCT05373043
- Testing
- Mitoquinone
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Long COVID
DAOIB for the Treatment of Brain Fog
This is a 24-week open trial. We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks.
- Trial name
- NCT05764538
- Testing
- DAOIB
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital
Post COVID Syndrome Long Covid
Observational Study With CICR-NAM as a Food for Special Medicinal Purposes in Post-COVID Syndrome (PCS)
In patients with post-COVID syndrome, changes in tryptophan metabolism, energy metabolism, and the gut microbiome may occur. In an earlier nutritional study, patients with COVID-19 recovered their physical performance more…
- Trial name
- CICR-NAM-PCS (NCT07798570)
- Testing
- CICR-NAM
- Volunteers
- 100 people
- Sponsor
- University Hospital Schleswig-Holstein
Smell Dysfunction, Olfactory Disorder
Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)
Persistent smell loss that can include diminished or distorted smell function is a common symptom of long COVID syndrome. There are limited treatment options for long COVID-related smell loss.
- Conditions
- Smell Dysfunction, Olfactory Disorder, Long COVID
- Trial name
- NCT05855369
- Testing
- Trigeminal Nerve Stimulation (TNS), Active Smell Training (ST)
- Where
- United States
- Volunteers
- 145 people
- Sponsor
- Medical University of South Carolina
Long COVID
Water-based Activity to Enhance Recovery in Long COVID-19
This two-year study will evaluate the feasibility and safety of an exercise + cognitive training program to improve neurological symptoms of long-COVID.
- Trial name
- NCT06142253
- Testing
- WATER+CT, Usual Care
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- VA Office of Research and Development
SARS CoV-2 Post-Acute Sequelae
Long-Term Study of COVID-19 Infection and Long COVID
This study will examine how common Long COVID is and how symptoms may persist over time in people who have previously had COVID-19.
- Trial name
- PASC (NCT07781501)
- Testing
- This study is observational. Only patients who have previously tested positive for SARS-CoV-2 infection or are experiencing ongoing symptoms.
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of North Carolina, Chapel Hill
Long Covid-19
LOng COvid COmorbidities: Endocrine,Metabolic,Neuropsychiatric,Muscle,Cardiovascular,Pulmonary,Dermatologic Dysfunctions
Considering the compelling amount of studies focused on patients in the active phase of COVID-19 disease and the scarcity of studies focused on patient cured from disease aimed at evaluating the sequelae of SARS-CoV-2 infection…
- Trial name
- LO-COCO (NCT05293366)
- Testing
- Assessments of endocrinological phenotypes of LO-COCO patients, Assessment of muscular phenotypes of LO-COCO patients, Assessment of neuropsychiatric phenotypes of LO-COCO patients
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Federico II University
Multisystem Inflammatory Syndrome in Children (MIS-C), SARS-CoV-2 Infection
Cardiovascular Assessment 5 Years After MIS-C
Multisystem inflammatory syndrome in children (MIS-C) is a severe complication associated with SARS-CoV-2 infection that frequently affects the cardiovascular system.
- Trial name
- NCT07659847
- Where
- Poland
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Long COVID Fatigue
Exploring the Therapeutic Effects of Creatine Supplementation for Long COVID-19
Individuals living with Long COVID often experiencing a degree of undue fatigue after physical or cognitive exertion secondary to the condition, timed post-exertional malaise 9PEM).
- Trial name
- NCT06992414
- Testing
- Creatine monohydrate
- Volunteers
- 24 people
- Sponsor
- University of Calgary
Long COVID
A Study to Assess Anktiva in Patients With Long Covid-19.
This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.
- Trial name
- INTERRUPT_LC (NCT07108036)
- Testing
- N-803 (IL-15 Superagonist)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- ImmunityBio, Inc.